Company Overview of MyoKardia, Inc.
MyoKardia, Inc. develops a pipeline of small molecule therapeutics that addresses clinical needs for patients with genetic heart diseases. The company was founded in 2012 and is based in South San Francisco, California.
400 East Jamie Court
South San Francisco, CA 94080
Founded in 2012
Key Executives for MyoKardia, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2014.
MyoKardia, Inc. Key Developments
MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015
Feb 18 15
MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.
MyoKardia, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:30 PM
Jan 6 15
MyoKardia, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Tassos Gianakakos, Chief Executive Officer and Director.
Sanofi and MyoKardia, Inc. Announce Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease
Sep 17 14
Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia`s pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction. The collaboration, representing one of the research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs. Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM). The collaboration provides up to $200 million in equity investments, milestone payments and research and development services through 2018, of which $45 million has already been received in an upfront licensing fee and an initial equity investment. In addition, Sanofi and MyoKardia will equally share development costs on the HCM programs following initial demonstration of efficacy in patients, with Sanofi fully covering the development costs of the DCM program. The collaboration is an outgrowth of Sanofi`s Sunrise initiative, a strategic partnership model that seeks to invest in early stage opportunities that align with Sanofi`s expert development and commercialization abilities. The commitment of resources from Sanofi will accelerate and broaden MyoKardia`s basic disease research and will support the shared commitment of bringing desperately needed therapies to patients. Within the collaboration, MyoKardia will drive research and worldwide development activities through early human efficacy studies. Thereafter, MyoKardia will lead worldwide development and U.S. commercial activities for the two HCM programs, where it has retained product rights, and Sanofi will lead global development and commercial activities for DCM where it has obtained worldwide rights, and ex-U.S. regulatory and commercial activities to the two HCM programs where it has ex-U.S. commercialization rights. Sanofi also has the option to co-promote in the U.S. for potential expanded cardiovascular diseases outside of the genetically targeted indications for either of the HCM programs, with MyoKardia having the option to co-promote the DCM program in the U.S.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 1, 2014